Skip to main content
SpringerLink
Log in

Association of COPD and Lung Cancer: How Does COPD Management Change the Outcome of Treatment of Lung Cancer?

  • Chapter
  • First Online:
Chronic Obstructive Pulmonary Disease

  • 3090 Accesses

Abstract

Chronic obstructive pulmonary disease (COPD) and lung cancer are caused by cigarette smoking, and there is increasing evidence linking the two diseases beyond a common etiology. COPD is widely considered to be a preneoplastic condition of smoking-related lung cancer. However, COPD is an independent risk factor for lung cancer and suggests some selected COPD phenotype in high-risk patients associates the development of lung cancer. Lung cancer patients with COPD have a significantly worse outcome than those without COPD. Thus, screening of patients with COPD for early detection of lung cancer using biomarkers and computed tomography has been suggested to improve outcomes. However, this approach of increased surveillance is hampered by the lack of sensitivity of treatment and the resulting large number of false-positive diagnoses. Improved understanding of the links between COPD and lung cancer and biomarkers that are more reliable may make this approach viable. In future, it may be possible to treat COPD patients with targeted therapies to reduce the risk of development of lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hoffmann D, Hoffmann I. The changing cigarette, 1950–1995. J Toxicol Environ Health. 1997;50(4):307–64.

    Article  CAS  PubMed  Google Scholar 

  2. Araya J, Cambier S, Markovics JA, Wolters P, Jablons D, Hill A, et al. Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients. J Clin Invest. 2007;117(11):3551–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell. 2005;121(6):823–35.

    Article  CAS  PubMed  Google Scholar 

  4. Houghton AM, Mouded M, Shapiro SD. Common origins of lung cancer and COPD. Nat Med. 2008;14(10):1023–4.

    Article  CAS  PubMed  Google Scholar 

  5. Rodriguez-Roisin R, Soriano JB. Chronic obstructive pulmonary disease with lung cancer and/or cardiovascular disease. Proc Am Thorac Soc. 2008;5(8):842–7.

    Article  PubMed  Google Scholar 

  6. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J. 2009;34(2):380–6.

    Article  CAS  PubMed  Google Scholar 

  7. de Torres JP, Bastarrika G, Wisnivesky JP, Alcaide AB, Campo A, Seijo LM, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest. 2007;132(6):1932–8.

    Article  PubMed  Google Scholar 

  8. Zulueta JJ, Wisnivesky JP, Henschke CI, Yip R, Farooqi AO, McCauley DI, et al. Emphysema scores predict death from COPD and lung cancer. Chest. 2012;141(5):1216–23.

    Article  PubMed  Google Scholar 

  9. Li Y, Swensen SJ, Karabekmez LG, Marks RS, Stoddard SM, Jiang R, et al. Effect of emphysema on lung cancer risk in smokers: a computed tomography-based assessment. Cancer Prev Res (Phila). 2011;4(1):43–50.

    Article  Google Scholar 

  10. Maldonado F, Bartholmai BJ, Swensen SJ, Midthun DE, Decker PA, Jett JR. Are airflow obstruction and radiographic evidence of emphysema risk factors for lung cancer? A nested case–control study using quantitative emphysema analysis. Chest. 2010;138(6):1295–302.

    Article  PubMed  Google Scholar 

  11. Wilson DO, Weissfeld JL, Balkan A, Schragin JG, Fuhrman CR, Fisher SN, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med. 2008;178(7):738–44.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Wille MM, Dirksen A, Ashraf H, Saghir Z, Bach KS, Brodersen J, et al. Results of the randomized Danish lung cancer screening trial with focus on high risk profiling. Am J Respir Crit Care Med. 2016;193(5):542–51.

    Article  CAS  PubMed  Google Scholar 

  13. Young RP, Duan F, Chiles C, Hopkins RJ, Gamble GD, Greco EM, et al. Airflow limitation and histology shift in the national lung screening trial. The NLST-ACRIN cohort substudy. Am J Respir Crit Care Med. 2015;192(9):1060–7.

    Article  PubMed  Google Scholar 

  14. National Lung Screening Trial Research T, Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, et al. The National Lung Screening Trial: overview and study design. Radiology. 2011;258(1):243–53.

    Article  Google Scholar 

  15. Bulut I, Arbak P, Coskun A, Balbay O, Annakkaya AN, Yavuz O, et al. Comparison of serum CA 19.9, CA 125 and CEA levels with severity of chronic obstructive pulmonary disease. Med Princ Pract. 2009;18(4):289–93.

    Article  CAS  PubMed  Google Scholar 

  16. Hillas G, Moschos C, Dimakou K, Vlastos F, Avgeropoulou S, Christakopoulou I, et al. Carcinoembryonic antigen, neuron-specific enolase and cytokeratin fragment 19 (CYFRA 21–1) levels in induced sputum of lung cancer patients. Scand J Clin Lab Invest. 2008;68(7):542–7.

    Article  CAS  PubMed  Google Scholar 

  17. Sanguinetti CM, Riccioni G, Marchesani F, Pela R, Cecarini L. Bronchoalveolar lavage fluid level of carcinoembryonic antigen in the diagnosis of peripheral lung cancer. Monaldi Arch Chest Dis. 1995;50(3):177–82.

    CAS  PubMed  Google Scholar 

  18. Farlow EC, Patel K, Basu S, Lee BS, Kim AW, Coon JS, et al. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res. 2010;16(13):3452–62.

    Article  CAS  PubMed  Google Scholar 

  19. Mattioni M, Chinzari P, Soddu S, Strigari L, Cilenti V, Mastropasqua E. Serum p53 antibody detection in patients with impaired lung function. BMC Cancer. 2013;13:62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Szpechcinski A, Chorostowska-Wynimko J, Struniawski R, Kupis W, Rudzinski P, Langfort R, et al. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease. Br J Cancer. 2015;113(3):476–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 2008;8(5):329–40.

    Article  CAS  PubMed  Google Scholar 

  22. Ilie M, Hofman V, Long-Mira E, Selva E, Vignaud JM, Padovani B, et al. “Sentinel” circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One. 2014;9(10):e111597.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Laniado-Laborin R. Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 century. Int J Environ Res Public Health. 2009;6(1):209–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Yang P, Sun Z, Krowka MJ, Aubry MC, Bamlet WR, Wampfler JA, et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med. 2008;168(10):1097–103.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Yang P, Bamlet WR, Sun Z, Ebbert JO, Aubry MC, Krowka MJ, et al. Alpha1-antitrypsin and neutrophil elastase imbalance and lung cancer risk. Chest. 2005;128(1):445–52.

    Article  CAS  PubMed  Google Scholar 

  26. Dialyna IA, Miyakis S, Georgatou N, Spandidos DA. Genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes and lung cancer risk. Oncol Rep. 2003;10(6):1829–35.

    CAS  PubMed  Google Scholar 

  27. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet. 2008;40(5):616–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452(7187):633–7.

    Article  CAS  PubMed  Google Scholar 

  29. Du Y, Xue Y, Xiao W. Association of IREB2 gene rs2568494 polymorphism with risk of chronic obstructive pulmonary disease: a meta-analysis. Med Sci Monit. 2016;22:177–82.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Liu Y, Liu P, Wen W, James MA, Wang Y, Bailey-Wilson JE, et al. Haplotype and cell proliferation analyses of candidate lung cancer susceptibility genes on chromosome 15q24-25.1. Cancer Res. 2009;69(19):7844–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Young RP, Whittington CF, Hopkins RJ, Hay BA, Epton MJ, Black PN, et al. Chromosome 4q31 locus in COPD is also associated with lung cancer. Eur Respir J. 2010;36(6):1375–82.

    Article  CAS  PubMed  Google Scholar 

  32. Young RP, Hopkins RJ, Hay BA, Whittington CF, Epton MJ, Gamble GD. FAM13A locus in COPD is independently associated with lung cancer – evidence of a molecular genetic link between COPD and lung cancer. Appl Clin Genet. 2011;4:1–10.

    PubMed  Google Scholar 

  33. Walser T, Cui X, Yanagawa J, Lee JM, Heinrich E, Lee G, et al. Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc. 2008;5(8):811–5.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Yang L, Yang X, Ji W, Deng J, Qiu F, Yang R, et al. Effects of a functional variant c.353T > C in snai1 on risk of two contextual diseases. Chronic obstructive pulmonary disease and lung cancer. Am J Respir Crit Care Med. 2014;189(2):139–48.

    CAS  PubMed  Google Scholar 

  35. Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, Winters SA, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. 2002;62(8):2370–7.

    CAS  PubMed  Google Scholar 

  36. Guzman L, Depix MS, Salinas AM, Roldan R, Aguayo F, Silva A, et al. Analysis of aberrant methylation on promoter sequences of tumor suppressor genes and total DNA in sputum samples: a promising tool for early detection of COPD and lung cancer in smokers. Diagn Pathol. 2012;7:87.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Lewis A, Riddoch-Contreras J, Natanek SA, Donaldson A, Man WD, Moxham J, et al. Downregulation of the serum response factor/miR-1 axis in the quadriceps of patients with COPD. Thorax. 2012;67(1):26–34.

    Article  PubMed  Google Scholar 

  38. Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis. 2010;31(1):37–49.

    Article  CAS  PubMed  Google Scholar 

  39. Williams AE, Perry MM, Moschos SA, Larner-Svensson HM, Lindsay MA. Role of miRNA-146a in the regulation of the innate immune response and cancer. Biochem Soc Trans. 2008;36(Pt 6):1211–5.

    Article  CAS  PubMed  Google Scholar 

  40. Makita H, Nasuhara Y, Nagai K, Ito Y, Hasegawa M, Betsuyaku T, et al. Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax. 2007;62(11):932–7.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Petrache I, Fijalkowska I, Zhen L, Medler TR, Brown E, Cruz P, et al. A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. Am J Respir Crit Care Med. 2006;173(11):1222–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. de Torres JP, Marin JM, Casanova C, Cote C, Carrizo S, Cordoba-Lanus E, et al. Lung cancer in patients with chronic obstructive pulmonary disease– incidence and predicting factors. Am J Respir Crit Care Med. 2011;184(8):913–9.

    Article  PubMed  Google Scholar 

  43. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.

    Article  CAS  PubMed  Google Scholar 

  44. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Lee KY, Ho SC, Chan YF, Wang CH, Huang CD, Liu WT, et al. Reduced nuclear factor-kappaB repressing factor: a link toward systemic inflammation in COPD. Eur Respir J. 2012;40(4):863–73.

    Article  CAS  PubMed  Google Scholar 

  46. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005;352(19):1967–76.

    Article  CAS  PubMed  Google Scholar 

  47. Parimon T, Chien JW, Bryson CL, McDonell MB, Udris EM, Au DH. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(7):712–9.

    Article  CAS  PubMed  Google Scholar 

  48. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–89.

    Article  CAS  PubMed  Google Scholar 

  49. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer. 2003;3(4):276–85.

    Article  CAS  PubMed  Google Scholar 

  50. Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2009;301(1):52–62.

    Article  CAS  PubMed  Google Scholar 

  51. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005;294(1):56–65.

    Article  CAS  PubMed  Google Scholar 

  52. van Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst. 2000;92(12):977–86.

    Article  PubMed  Google Scholar 

  53. Jackson AL, Zhou B, Kim WY. HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer. Expert Opin Ther Targets. 2010;14(10):1047–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer. 2001;85(6):881–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Kim WY, Perera S, Zhou B, Carretero J, Yeh JJ, Heathcote SA, et al. HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest. 2009;119(8):2160–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Kaya A, Ciledag A, Gulbay BE, Poyraz BM, Celik G, Sen E, et al. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med. 2004;98(7):632–6.

    Article  PubMed  Google Scholar 

  57. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.

    Article  CAS  PubMed  Google Scholar 

  58. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 2000;106(11):1311–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Kranenburg AR, de Boer WI, Alagappan VK, Sterk PJ, Sharma HS. Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(2):106–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Punturieri A, Szabo E, Croxton TL, Shapiro SD, Dubinett SM. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst. 2009;101(8):554–9.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med. 2010;16(2):219–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Vignola AM, Riccobono L, Mirabella A, Profita M, Chanez P, Bellia V, et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med. 1998;158(6):1945–50.

    Article  CAS  PubMed  Google Scholar 

  63. Linder R, Ronmark E, Pourazar J, Behndig A, Blomberg A, Lindberg A. Serum metalloproteinase-9 is related to COPD severity and symptoms – cross-sectional data from a population based cohort-study. Respir Res. 2015;16:28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A. 2006;103(33):12493–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436(7050):518–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. D’Armiento J, Dalal SS, Okada Y, Berg RA, Chada K. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell. 1992;71(6):955–61.

    Article  PubMed  Google Scholar 

  67. Joos L, He JQ, Shepherdson MB, Connett JE, Anthonisen NR, Pare PD, et al. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet. 2002;11(5):569–76.

    Article  CAS  PubMed  Google Scholar 

  68. Hunninghake GM, Cho MH, Tesfaigzi Y, Soto-Quiros ME, Avila L, Lasky-Su J, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med. 2009;361(27):2599–608.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Houghton AM, Grisolano JL, Baumann ML, Kobayashi DK, Hautamaki RD, Nehring LC, et al. Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res. 2006;66(12):6149–55.

    Article  CAS  PubMed  Google Scholar 

  70. Magnussen H, Watz H, Kirsten A, Wang M, Wray H, Samuelsson V, et al. Safety and tolerability of an oral MMP-9 and −12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: a randomised controlled 6-week trial. Pulm Pharmacol Ther. 2011;24(5):563–70.

    Article  CAS  PubMed  Google Scholar 

  71. Shepherd FA, Sridhar SS. Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer. 2003;41 Suppl 1:S63–72.

    Article  PubMed  Google Scholar 

  72. Hirsh L, Dantes A, Suh BS, Yoshida Y, Hosokawa K, Tajima K, et al. Phosphodiesterase inhibitors as anti-cancer drugs. Biochem Pharmacol. 2004;68(6):981–8.

    Article  CAS  PubMed  Google Scholar 

  73. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009;30(3):377–86.

    Article  CAS  PubMed  Google Scholar 

  74. Mao JT, Roth MD, Fishbein MC, Aberle DR, Zhang ZF, Rao JY, et al. Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila). 2011;4(7):984–93.

    Article  CAS  Google Scholar 

  75. Reckamp KL, Koczywas M, Cristea MC, Dowell JE, Wang HJ, Gardner BK, et al. Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer. Cancer. 2015;121(18):3298–306.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Roh GS, Yi CO, Cho YJ, Jeon BT, Nizamudtinova IT, Kim HJ, et al. Anti-inflammatory effects of celecoxib in rat lungs with smoke-induced emphysema. Am J Physiol Lung Cell Mol Physiol. 2010;299(2):L184–91.

    Article  CAS  PubMed  Google Scholar 

  77. Keith RL, Miller YE, Hudish TM, Girod CE, Sotto-Santiago S, Franklin WA, et al. Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res. 2004;64(16):5897–904.

    Article  CAS  PubMed  Google Scholar 

  78. Lange A, Gustke H, Glassmeier G, Heine M, Zangemeister-Wittke U, Schwarz JR, et al. Neuronal differentiation by indomethacin and IBMX inhibits proliferation of small cell lung cancer cells in vitro. Lung Cancer. 2011;74(2):178–87.

    Article  PubMed  Google Scholar 

  79. Schuller HM, Plummer 3rd HK, Bochsler PN, Dudric P, Bell JL, Harris RE. Co-expression of beta-adrenergic receptors and cyclooxygenase-2 in pulmonary adenocarcinoma. Int J Oncol. 2001;19(3):445–9.

    CAS  PubMed  Google Scholar 

  80. Lee SU, Ahn KS, Sung MH, Park JW, Ryu HW, Lee HJ, et al. Indacaterol inhibits tumor cell invasiveness and MMP-9 expression by suppressing IKK/NF-kappaB activation. Mol Cells. 2014;37(8):585–91.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  81. Zhao Q, Gu X, Zhang C, Lu Q, Chen H, Xu L. Blocking M2 muscarinic receptor signaling inhibits tumor growth and reverses epithelial-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC). Cancer Biol Ther. 2015;16(4):634–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Zhao Q, Yue J, Zhang C, Gu X, Chen H, Xu L. Inactivation of M2 AChR/NF-kappaB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC). Oncotarget. 2015;6(30):29335–46.

    PubMed  PubMed Central  Google Scholar 

  83. Lin G, Sun L, Wang R, Guo Y, Xie C. Overexpression of muscarinic receptor 3 promotes metastasis and predicts poor prognosis in non-small-cell lung cancer. J Thorac Oncol. 2014;9(2):170–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Xu R, Shang C, Zhao J, Han Y, Liu J, Chen K, et al. Activation of M3 muscarinic receptor by acetylcholine promotes non-small cell lung cancer cell proliferation and invasion via EGFR/PI3K/AKT pathway. Tumour Biol. 2015;36(6):4091–100.

    Article  CAS  PubMed  Google Scholar 

  85. Zhang S, Togo S, Minakata K, Gu T, Ohashi R, Tajima K, et al. Distinct roles of cholinergic receptors in small cell lung cancer cells. Anticancer Res. 2010;30(1):97–106.

    PubMed  Google Scholar 

  86. Hua N, Wei X, Liu X, Ma X, He X, Zhuo R, et al. A novel muscarinic antagonist R2HBJJ inhibits non-small cell lung cancer cell growth and arrests the cell cycle in G0/G1. PLoS One. 2012;7(12), e53170.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Hashimoto N, Matsuzaki A, Okada Y, Imai N, Iwano S, Wakai K, et al. Clinical impact of prevalence and severity of COPD on the decision-making process for therapeutic management of lung cancer patients. BMC Pulm Med. 2014;14:14.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Lugg ST, Agostini PJ, Tikka T, Kerr A, Adams K, Bishay E, et al. Long-term impact of developing a postoperative pulmonary complication after lung surgery. Thorax. 2016;71(2):171–6.

    Article  PubMed  Google Scholar 

  89. Kobayashi S, Suzuki S, Niikawa H, Sugawara T, Yanai M. Preoperative use of inhaled tiotropium in lung cancer patients with untreated COPD. Respirology. 2009;14(5):675–9.

    Article  PubMed  Google Scholar 

  90. Sekine Y, Suzuki H, Yamada Y, Koh E, Yoshino I. Severity of chronic obstructive pulmonary disease and its relationship to lung cancer prognosis after surgical resection. Thorac Cardiovasc Surg. 2013;61(2):124–30.

    PubMed  Google Scholar 

  91. Kuo CH, Wu CY, Lee KY, Lin SM, Chung FT, Lo YL, et al. Chronic obstructive pulmonary disease in stage I non-small cell lung cancer that underwent anatomic resection: the role of a recurrence promoter. COPD. 2014;11(4):407–13.

    Article  PubMed  Google Scholar 

  92. Putila J, Guo NL. Combining COPD with clinical, pathological and demographic information refines prognosis and treatment response prediction of non-small cell lung cancer. PLoS One. 2014;9(6), e100994.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  93. Izquierdo JL, Resano P, El Hachem A, Graziani D, Almonacid C, Sanchez IM. Impact of COPD in patients with lung cancer and advanced disease treated with chemotherapy and/or tyrosine kinase inhibitors. Int J Chron Obstruct Pulmon Dis. 2014;9:1053–8.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Lim JU, Yeo CD, Rhee CK, Kim YH, Park CK, Kim JS, et al. Chronic obstructive pulmonary disease-related non-small-cell lung cancer exhibits a low prevalence of EGFR and ALK driver mutations. PLoS One. 2015;10(11), e0142306.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  95. Schiavon M, Marulli G, Nannini N, Pasello G, Lunardi F, Balestro E, et al. COPD-related adenocarcinoma presents low aggressiveness morphological and molecular features compared to smoker tumours. Lung Cancer. 2014;86(3):311–7.

    Article  PubMed  Google Scholar 

  96. de Boer WI, Hau CM, van Schadewijk A, Stolk J, van Krieken JH, Hiemstra PS. Expression of epidermal growth factors and their receptors in the bronchial epithelium of subjects with chronic obstructive pulmonary disease. Am J Clin Pathol. 2006;125(2):184–92.

    Article  PubMed  CAS  Google Scholar 

  97. Woodruff PG, Wolff M, Hohlfeld JM, Krug N, Dransfield MT, Sutherland ER, et al. Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181(5):438–45.

    Article  CAS  PubMed  Google Scholar 

  98. Inoue T, Shiomi H, Oh RJ. Stereotactic body radiotherapy for Stage I lung cancer with chronic obstructive pulmonary disease: special reference to survival and radiation-induced pneumonitis. J Radiat Res. 2015;56(4):727–34.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Kimura T, Togami T, Takashima H, Nishiyama Y, Ohkawa M, Nagata Y. Radiation pneumonitis in patients with lung and mediastinal tumours: a retrospective study of risk factors focused on pulmonary emphysema. Br J Radiol. 2012;85(1010):135–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Takeda A, Kunieda E, Ohashi T, Aoki Y, Oku Y, Enomoto T, et al. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy. Chest. 2012;141(4):858–66.

    Article  PubMed  Google Scholar 

  101. Ishijima M, Nakayama H, Itonaga T, Tajima Y, Shiraishi S, Okubo M, et al. Patients with severe emphysema have a low risk of radiation pneumonitis following stereotactic body radiotherapy. Br J Radiol. 2015;88(1046):20140596.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Grumelli S, Corry DB, Song LZ, Song L, Green L, Huh J, et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med. 2004;1(1), e8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  103. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549–55.

    Article  CAS  PubMed  Google Scholar 

  104. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol. 2006;16(1):3–15.

    Article  CAS  PubMed  Google Scholar 

  105. Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi FS, Oxnard GR, Jackman DM, Jänne PA. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-Mutant Lung Cancer. J Thorac Oncol. 2015;10(12):1726–35. doi:10.1097/JTO.0000000000000687.

  106. Yang Y, Pang Z, Ding N, Dong W, Ma W, Li Y, Du J, Liu Q. The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis. Oncotarget. 2016. doi:10.18632/oncotarget.11291.

  107. Kalathil SG, Lugade AA, Pradhan V, Miller A, Parameswaran GI, Sethi S, et al. T-regulatory cells and programmed death 1+ T cells contribute to effector T-cell dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;190(1):40–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Yap KL, Ada GL, McKenzie IF. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature. 1978;273(5659):238–9.

    Article  CAS  PubMed  Google Scholar 

  109. Topham DJ, Tripp RA, Doherty PC. CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol. 1997;159(11):5197–200.

    CAS  PubMed  Google Scholar 

  110. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2008;177(10):1164–70.

    Article  PubMed  Google Scholar 

  111. Mylonaki E, Manika K, Zarogoulidis P, Domvri K, Voutsas V, Zarogoulidis K, et al. In vivo synergistic cytogenetic effects of aminophylline on lymphocyte cultures from patients with lung cancer undergoing chemotherapy. Mutat Res. 2012;740(1–2):1–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Respiratory Medicine, Juntendo University School of Medicine & Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan

    Shinsaku Togo, Yukiko Namba & Kazuhisa Takahashi

  2. Research Institute for Diseases of Old Age, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan

    Shinsaku Togo, Yukiko Namba & Kazuhisa Takahashi

Authors
  1. Shinsaku Togo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yukiko Namba
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuhisa Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shinsaku Togo .

Editor information

Editors and Affiliations

  1. Department of Respiratory Medicine, Tokyo Medical University Ibaraki Medical Center, Ibaraki, Japan

    Hiroyuki Nakamura

  2. Department of Respiratory Medicine, Tokyo Medical University Ibaraki Medical Center, Ibaraki, Japan

    Kazutetsu Aoshiba

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media Singapore

About this chapter

Cite this chapter

Togo, S., Namba, Y., Takahashi, K. (2017). Association of COPD and Lung Cancer: How Does COPD Management Change the Outcome of Treatment of Lung Cancer?. In: Nakamura, H., Aoshiba, K. (eds) Chronic Obstructive Pulmonary Disease. Respiratory Disease Series: Diagnostic Tools and Disease Managements. Springer, Singapore. https://doi.org/10.1007/978-981-10-0839-9_18

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-0839-9_18

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-0838-2

  • Online ISBN: 978-981-10-0839-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation